| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/INFDIS/163.3.579 |
| P698 | PubMed publication ID | 1704903 |
| P2093 | author name string | Rubin M | |
| Walsh TJ | |||
| Pizzo PA | |||
| Roilides E | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 579-583 | |
| P577 | publication date | 1991-03-01 | |
| P1433 | published in | Journal of Infectious Diseases | Q4051141 |
| P1476 | title | Granulocyte colony-stimulating factor enhances the phagocytic and bactericidal activity of normal and defective human neutrophils | |
| P478 | volume | 163 |
| Q83232958 | 3 Granulocyte Concentrates |
| Q43112430 | A bispecific antibody composed of a nonneutralizing antibody to the gp41 immunodominant region and an anti-CD89 antibody directs broad human immunodeficiency virus destruction by neutrophils |
| Q38108962 | Abnormalities in host defense associated with HIV infection |
| Q47902220 | Activation of human leukocytes on tantalum trabecular metal in comparison to commonly used orthopedic metal implant materials. |
| Q38720387 | Acute-on-chronic liver failure: terminology, mechanisms and management |
| Q34092221 | Adjunctive Therapies for Sepsis and Septic Shock |
| Q46485748 | Amelioration of neutrophil membrane function underlies granulocyte-colony stimulating factor action in glycogen storage disease 1b. |
| Q33998510 | Angiotensin II increases host resistance to peritonitis |
| Q42557463 | Antifungal combination therapy with granulocyte colony-stimulating factor and fluconazole in experimental disseminated candidiasis |
| Q29617908 | Aspergillus fumigatus and aspergillosis |
| Q50178652 | Association between elevated plasma granulocyte colony-stimulating factor and the degree of surgical stress in patients undergoing gastrointestinal surgery |
| Q36444863 | Attenuation of the bacterial load in blood by pretreatment with granulocyte-colony-stimulating factor protects rats from fatal outcome and brain damage during Streptococcus pneumoniae meningitis |
| Q78831019 | Bactericidal activity response of blood neutrophils from critically ill patients to in vitro granulocyte colony-stimulating factor stimulation |
| Q40630439 | Biological activities of hematopoietic growth factors that lead to future clinical application |
| Q81605268 | Biological response modifiers and infectious diseases: actual and potential therapeutic agents |
| Q40489140 | Biologicals and Hematopoietic Cytokines in Prevention or Treatment of Infections in Immunocompromised Hosts |
| Q43923492 | Changes in cellular immunity during chemotherapy for testicular cancer |
| Q48086934 | Cloning and sequencing of an ovine granulocyte colony-stimulating factor cDNA. |
| Q73235183 | Colony-Stimulating Factors in the Therapeutic Approach to Sepsis |
| Q35164487 | Colony-stimulating factors in the clinic |
| Q71814496 | Combined effect of human neutrophils, ceftazidime and granulocyte colony-stimulating factor on killing ofEscherichia coli |
| Q40561085 | Common emergencies in cancer medicine: infectious and treatment-related syndromes, Part I. |
| Q64235789 | Comparative Assessment of Aspergillosis by Virtual Infection Modeling in Murine and Human Lung |
| Q35120830 | Critical influence of timing of administration of granulocyte colony-stimulating factor on antibacterial effect in experimental endocarditis due to Pseudomonas aeruginosa |
| Q40598683 | Cytokines in the treatment of fungal infections |
| Q78196556 | Defective functional activity and accelerated apoptosis in neutrophils from children with cancer are differentially corrected by granulocyte and granulocyte-macrophage colony stimulating factors in vitro |
| Q35112318 | Effect of cefodizime and ceftriaxone on phagocytic function in patients with severe infections |
| Q39784575 | Effect of granulocyte colony-stimulating factor on the candidacidal activity of polymorphonuclear neutrophils and their collaboration with fluconazole |
| Q39741689 | Effect of interleukin-8 and granulocyte colony-stimulating factor on priming and activation of bovine neutrophils. |
| Q72105356 | Effects of Perioperative Granulocyte Colony‐Stimulating Factor on Horses With Ascending Colonic Ischemia |
| Q51677069 | Effects of exogenous recombinant human granulocyte colony-stimulating factor (filgrastim, rhG-CSF) on neutrophils of critically ill patients with systemic inflammatory response syndrome depend on endogenous G-CSF plasma concentrations on admission. |
| Q35553643 | Effects of granulocyte and granulocyte-macrophage colony-stimulating factors in a neutropenic murine model of trichosporonosis. |
| Q47901682 | Effects of granulocyte colony-stimulating factor (G-CSF) treatment on granulocyte function and receptor expression in patients with ventilator-dependent pneumonia |
| Q44394263 | Effects of granulocyte-colony stimulating factor in the treatment of diabetic foot infection |
| Q42210083 | Effects of granulocyte-colony stimulating factor on peritoneal defense mechanisms and bacterial translocation after administration of systemic chemotherapy in rats |
| Q77597620 | Effects of r-metHuG-CSF on polymorphonuclear leucocyte kinetics and function in patients on continuous ambulatory peritoneal dialysis |
| Q28367589 | Effects of recombinant granulocyte-colony stimulating factor administration during Mycobacterium avium infection in mice |
| Q45248794 | Enhanced clearance of a multiple antibiotic resistant Staphylococcus aureus in rats treated with PGG-glucan is associated with increased leukocyte counts and increased neutrophil oxidative burst activity |
| Q72081824 | Enhancement of in vitro bactericidal activity of neutrophils from trauma patients in the presence of granulocyte colony-stimulating factor |
| Q33618882 | Enhancement of oxidative response and damage caused by human neutrophils to Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon |
| Q42011416 | Evidence for bistable bacteria-neutrophil interaction and its clinical implications |
| Q46592144 | Experimental systemic murine aspergillosis: treatment with polyene and caspofungin combination and G-CSF. |
| Q74348626 | Expression, purification, and in vitro biological activities of recombinant bovine granulocyte-colony stimulating factor |
| Q40660810 | Fever in the neutropenic host |
| Q37620301 | G-CSF drives a posttraumatic immune program that protects the host from infection |
| Q73613791 | Granulocyte colony-stimulating factor (G-CSF) serum levels in surgical intensive care patients |
| Q36620210 | Granulocyte colony-stimulating factor (G-CSF) transiently suppresses mitogen-stimulated T-cell proliferative response |
| Q37384429 | Granulocyte colony-stimulating factor administration to HIV-infected subjects augments reduced leukotriene synthesis and anticryptococcal activity in neutrophils |
| Q38942905 | Granulocyte colony-stimulating factor and an in vitro whole blood model of melioidosis. |
| Q33697679 | Granulocyte colony-stimulating factor and azole antifungal therapy in murine aspergillosis: role of immune suppression |
| Q41101389 | Granulocyte colony-stimulating factor and modulation of inflammatory cells in sepsis |
| Q40672871 | Granulocyte colony-stimulating factor does not enhance phagocytosis or microbicidal activity of human mature polymorphonuclear neutrophils in vitro. |
| Q73031338 | Granulocyte colony-stimulating factor for the treatment of biomaterial-associated staphylococcal infections in-vitro |
| Q67464763 | Granulocyte colony-stimulating factor treatment in AIDS patients |
| Q74404199 | Granulocyte colony-stimulating factor use is associated with decreased bacteremia and increased survival in neutropenic HIV-infected patients |
| Q35337940 | Granulocyte colony-stimulating factor: structure, function and physiology |
| Q35583664 | Granulocyte concentrates: how can we assess their quality? |
| Q41108743 | Granulocyte transfusions. Time for a second look |
| Q77534554 | Granulocyte-macrophage colony-stimulating factor (GM-CSF)-coated implants and their potential for reducing biomaterial-associated infection in neutropenic hosts |
| Q40833043 | Growth factors of the future |
| Q34527650 | Haematopoietic growth factors in children with neutropenia |
| Q41378002 | Hematopoietic growth factors in cancer patients with invasive fungal infections |
| Q33363758 | Hemophagocytosis exacerbated by G-CSF/GM-CSF treatment in a patient with myelodysplasia |
| Q36269642 | Immune dysfunction in acute alcoholic hepatitis. |
| Q35129044 | Immunomodulation of invasive fungal infections |
| Q35224457 | Immunomodulatory agents in the laboratory and clinic |
| Q51189168 | Impact of high-dose granulocyte transfusions in patients with cancer with candidemia: retrospective case-control analysis of 491 episodes of Candida species bloodstream infections. |
| Q40821063 | Impaired killing of Candida albicans by granulocytes mobilized for transfusion purposes: a role for granule components |
| Q54645297 | Inhibition of Candida albicans growth by murine peritoneal neutrophils and augmentation of the inhibitory activity by bacterial lipopolysaccharide and cytokines. |
| Q77712318 | Is there an effect of immunoglobulins and G-CSF on neutrophil phagocytic activity in preterm infants? |
| Q41377981 | Key issues concerning fungistatic versus fungicidal drugs |
| Q33897249 | Lenograstim: an update of its pharmacological properties and use in chemotherapy-induced neutropenia and related clinical settings |
| Q44054262 | Low-dose recombinant human granulocyte colony-stimulating factor therapy in children with symptomatic chronic idiopathic neutropenia |
| Q37641941 | Mechanisms of Cholera Toxin in the Modulation of TH17 Responses |
| Q24522461 | Melioidosis: epidemiology, pathophysiology, and management |
| Q39161241 | Mycobacterium tuberculosis-induced expression of granulocyte-macrophage colony stimulating factor is mediated by PI3-K/MEK1/p38 MAPK signaling pathway |
| Q36402342 | Neutropenia in HIV-Infected Kenyan Women Receiving Triple Antiretroviral Prophylaxis to Prevent Mother-to-Child HIV Transmission Is Not Associated with Serious Clinical Sequelae |
| Q98386860 | Neutrophil dysfunction predicts 90-day survival in patients with acute on chronic liver failure: A longitudinal case-control study |
| Q34072007 | New treatments in ulcer healing and wound infection |
| Q40664723 | Nontropical pyomyositis in patients with AIDS. |
| Q40932284 | Opportunistic infections in oncologic patients |
| Q47687878 | Pentoxifylline differentially regulates migration and respiratory burst activity of the neutrophil |
| Q44671474 | Polyene and cytokine treatment of experimental aspergillosis |
| Q33614894 | Prevention of corticosteroid-induced suppression of human polymorphonuclear leukocyte-induced damage of Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon |
| Q36670422 | Production and function of cytokines in natural and acquired immunity to Candida albicans infection |
| Q35137322 | Prospective randomized comparison of cefodizime versus cefuroxime for perioperative prophylaxis in patients undergoing coronary artery bypass grafting |
| Q40701026 | Pulmonary infiltrations in febrile patients with neutropenia. Risk factors and outcome under empirical antimicrobial therapy in a randomized multicenter study |
| Q84363216 | Purification and characterization of an immunogenic outer membrane protein of Shigella flexneri 2a |
| Q51536238 | Randomised placebo-controlled trial of granulocyte-colony stimulating factor in diabetic foot infection. |
| Q33981858 | Randomized prospective controlled trial of recombinant granulocyte colony-stimulating factor as adjunctive therapy for limb-threatening diabetic foot infection |
| Q40492213 | Recombinant Cytokines and Pulmonary Host Defense |
| Q40424119 | Recombinant Hematopoietic Growth Factors in Bone Marrow Transplantation |
| Q40391638 | Recombinant methionyl granulocyte colony-stimulating factor (filgrastim): a new dimension in immunotherapy |
| Q35810332 | Suppression of polymorphonuclear leukocyte bactericidal activity by suramin |
| Q64905694 | Synergy of simultaneous administration of ofloxacin and granulocyte colony-stimulating factor in killing of Escherichia coli by human neutrophils. |
| Q33743570 | Th17 cytokines and the gut mucosal barrier |
| Q54260140 | The Dual Role of Neutrophils in HIV Infection. |
| Q45790664 | The effects of human immunodeficiency virus infection on macrophage phagocytosis of Candida |
| Q36328685 | The immunocompromised host: HIV infection |
| Q40517931 | The role of hematopoietic growth factors in transfusion medicine. |
| Q41923884 | The role of polymorphonuclear neutrophils during HIV-1 infection |
| Q72085552 | Therapeutic efficacy of granulocyte colony stimulating factor against rat cecal ligation and puncture model |
| Q39782162 | Treatment of Staphylococcus aureus catheter-related infection and infective endocarditis with granulocyte colony-stimulating factor in the experimental rabbit model |
| Q41377990 | Trends in immunotherapy of fungal infections |
| Q33769906 | Tumor necrosis factor alpha enhances antifungal activities of polymorphonuclear and mononuclear phagocytes against Aspergillus fumigatus |
| Q92502928 | Tumour-associated neutrophils in patients with cancer |
| Q54339984 | Unconventional apoptosis of polymorphonuclear neutrophils (PMN): staurosporine delays exposure of phosphatidylserine and prevents phagocytosis by MΦ-2 macrophages of PMN. |
| Q40347002 | Usage of granulocyte colony-stimulating factor every 2 days is clinically useful and cost-effective for febrile neutropenia during early courses of chemotherapy |
| Q41501807 | Yersinia enterocolitica meningitis and septicaemia in a patient with acute lymphoblastic leukaemia |
Search more.